ClinicalTrials.gg
CompletedNCT01989325Updated Sep 16, 2020

A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma

A Phase 2 interventional study of Carfilzomib, proteasome inhibitor; intravenous and Filanesib, KSP(Eg5) inhibitor; intravenous in Advanced Multiple Myeloma, sponsored by Pfizer. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-16.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma — 1 open to participants now, 1 under way, 1 of them phase 3. Granulocyte Colony-Stimulating Factor · Multiple Myeloma.

Enrollment
8th of 28
77 · median 38
Started
2013
the only one that year
Phase 2
17 of 28
none open now
Registered
21st of 28
by date
Lead sponsor
2 of 28
Pfizer

Among the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, this one is the 8th largest by enrollment, is the only one that started in 2013, is one of 17 in phase 2, and was the 21st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

1 of the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Granulocyte Colony-Stimulating Factor

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a Phase 2 study during which patients with advanced multiple myeloma will receive either carfilzomib alone (single-agent) or carfilzomib in combination with investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of both single-agent carfilzomib and carfilzomib + filanesib in treating myeloma. Patients will be allowed to crossover from single-agent carfilzomib to carfilzomib + filanesib if disease progression occurs. Approximately 75 patients from the US will be enrolled in this study.

03

Conditions studied

  • Advanced Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Confirmed multiple myeloma with .
  • Disease to last myeloma regimen.
  • Patients must have received at least 2 prior treatment regimens, including bortezomib and an IMiD (e.g., lenalidomide, thalidomide, pomalidomide). Induction therapy and stem cell transplant ± maintenance are to be considered as a single regimen.
  • (ECOG) performance status of 0, 1 or 2 within 14 days prior to first dose of study treatment.
  • Adequate hematology, liver and renal function laboratory values within 14 days prior to first dose of study treatment.
  • Additional criteria exist.

Key Exclusion Criteria:

  • Prior treatment with carfilzomib, filanesib, or any other KSP inhibitor.
  • Past or current plasma cell leukemia.
  • Primary amyloidosis (amyloidosis associated with multiple myeloma is allowed).
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes).
  • Ongoing Grade 3 or Grade 4 peripheral neuropathy, or Grade 2 peripheral neuropathy with pain despite appropriate interventions, within 28 days prior to first dose of study treatment.
  • Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to first dose of study treatment.
  • Concomitant or previous malignancies (other than multiple myeloma) with less than a 2-year disease-free interval at the time of first dose of study treatment. Patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or Stage 1 prostate cancer are eligible irrespective of the time of diagnosis.
  • Known pulmonary hypertension of any severity.
  • Concurrent cardiac disease that, in the judgment of the Investigator, would make the patient inappropriate for study participation.
  • Known positive serology for the (HIV), active and/or .
  • Acute active infection requiring treatment.
  • Additional criteria exist.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Carfilzomib + Filanesib

    Single agent + Carfilzomib arm. Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information. Filgrastim to be administered per the approved product prescribing information and institutional guidelines.

    Drug: Carfilzomib, proteasome inhibitor; intravenous · Drug: Filanesib, KSP(Eg5) inhibitor; intravenous · Drug: Dexamethasone, steroid; oral or intravenous · Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

  • Experimental
    Carfilzomib

    Single agent arm. Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information.

    Drug: Carfilzomib, proteasome inhibitor; intravenous · Drug: Dexamethasone, steroid; oral or intravenous

Interventions

  • DrugCarfilzomib, proteasome inhibitor; intravenous

    multiple dose, single schedule

  • DrugFilanesib, KSP(Eg5) inhibitor; intravenous

    multiple dose, single schedule

  • DrugDexamethasone, steroid; oral or intravenous

    as indicated, per the carfilzomib prescribing information

  • DrugFilgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

    Drug pages: Granulocyte Colony-Stimulating Factor · Filgrastim

    standard of care

06

What researchers measure

Primary outcomes

  1. Assess the efficacy of both carfilzomib + study drug and single-agent carfilzomib in terms of progression-free survival.

    Time frame: 18 months

Secondary outcomes

  1. Assess the efficacy of both carfilzomib + study drug and single-agent carfilzomib in terms of objective response rate.

    Time frame: 18 months

  2. Assess the safety of both carfilzomib + study drug and single-agent carfilzomib in terms of adverse events, clinical laboratory tests and electrocardiograms.

    Time frame: 18 months

  3. Characterize the pharmacokinetics (PK) of study drug, carfilzomib and a carfilzomib metabolite in patients treated with carfilzomib + study drug in terms of plasma concentration-time profiles and model-based PK parameters.

    Time frame: 6 months

  4. Following crossover from single-agent carfilzomib, assess the efficacy of carfilzomib + study drug in terms of objective response rate.

    Time frame: 18 months

  5. Following crossover from single-agent carfilzomib, assess the safety of carfilzomib + study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.

    Time frame: 18 months

Other outcomes

  1. Evaluate patient serum levels of alpha 1-acid glycoprotein (AAG) at Baseline and during the treatment period.

    Time frame: 18 months

07

Study locations

22 sites
  • Genesis Cancer Center
    Hot Springs, Arkansas 71913, United States
  • UCLA
    Los Angeles, California 90095, United States
  • St. Joseph Heritage Healthcare
    Santa Rosa, California 95403, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33905, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
    Chicago, Illinois 60611, United States
  • Crescent City Research Consortium
    Marrero, Louisiana 70072, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Forrest General Cancer Center
    Hattiesburg, Mississippi 39401, United States
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
  • Memorial Sloan Kettering
    New York, New York 10065, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Oncology Hematology Care - Blue Ash
    Cincinnati, Ohio 45242, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Knight Cancer Institute at Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Prairie Lakes Health Care System
    Watertown, South Dakota 57201, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Simmons Cancer Center - UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • WVU - Mary Babb Randolph Cancer Center
    Morgantown, West Virginia 26506, United States
  • Medical College of Wisconsin Cancer Center
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Feb 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2013
First posted
Nov 21, 2013
Start
Nov 2013
Primary completionActual
Feb 2016
CompletionActual
May 2016
Results delay requested
Apr 15, 2016
Last update
Sep 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01989325
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 21, 2013
Start date
Nov 2013
Primary completion
Feb 2016
Completion
May 2016
Last update
Sep 16, 2020

Study contacts

Clinical Trial Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Filgrastim

Start the discussion